Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Soleno Therapeutics ( (SLNO) ) has shared an update.
On January 21, 2025, Soleno Therapeutics’ Board of Directors approved increases to the base salaries for fiscal year 2025 and the payment of cash bonuses for fiscal year 2024 for its named executive officers, along with certain equity awards. This decision reflects the company’s ongoing efforts to enhance its executive compensation structure, which may impact its strategic operations and stakeholder expectations.
More about Soleno Therapeutics
Soleno Therapeutics operates in the biotechnology industry, focusing on developing and commercializing products for the treatment of rare diseases and disorders.
YTD Price Performance: 5.64%
Average Trading Volume: 596,012
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.08B
For detailed information about SLNO stock, go to TipRanks’ Stock Analysis page.
